NCT03223610
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
At risk: Primary completion moved at least 8 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 401 versions: 5 with changes below, 45 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 1, 2026 to Aug 12, 2027
- Study completion pushed from Dec 1, 2027 to Dec 12, 2029
- New version filed on ClinicalTrials.gov
- Minor Enrollment target: 145 to 155v374
- Study Status, Study Descriptionv373
- Notable Primary completion date: Dec 1, 2025 to Dec 1, 2026
- Study completion date: Dec 1, 2026 to Dec 1, 2027
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
Drugs: Venetoclax, Ibrutinib, Prednisone, Revlimid (lenalidomide)
Biologicals: Obinutuzumab
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States